Drugs / ESPO
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03902691 Comparator | May 2019 → Feb 2021 | chronic kidney disease | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ESPO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03902691 ↗ |
| Modality | Protein / enzyme biologic | “ESPO (Recombinant Human Erythropoietin Injection）” NCT03902691 ↗ |
| Route | Subcutaneous | “Participants received ESPO by subcutaneous injection or subcutaneous injection weekly.” NCT03902691 ↗ |